Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples

Table 5 PD-L1 expression stratified by clinicopathologic features

Characteristic	PD-L1 TPS			Total (n)	Z	P value
Characteristic	< 1% n (%)	1–49% n (%)	≥50% n (%)	Total (n)	Z	P value
Total	32 (25.8)	45 (36.3)	47 (37.9)	124
Age, y				124	−1.038	0.299
≤ 55	13 (29.5)	17 (38.6)	14 (31.8)
> 55	19 (23.8)	28 (35)	33 (41.3)
Sex				124	−1.099	0.272
Male	23 (28.8)	29 (36.3)	28 (35.0)
Female	9 (20.5)	16 (36.4)	19 (43.2)
Diagnosis				119	−2.47	0.013^a
Adenocarcinoma	23 (21.3)	42 (38.9)	43 (39.8)	108
Smoking status				99	−1.944	0.052
Current or former	13 (32.5)	15 (37.5)	12 (30.0)
Never	9 (15.3)	24 (40.7)	26 (44.1)
Squamous cell carcinoma	7 (63.6)	2 (18.2)	2 (18.2)	11
Smoking status				8	−0.77	0.643
Current or former	4 (66.7)	2 (33.3)	0 (0.0)
Never	1 (50.0)	0 (0.0)	1 (50.0)
Smoking status				111	−2.63	0.009^a
Current or former	19 (38.0)	18 (36.0)	13 (26.0)
Never	10 (16.4)	24 (39.3)	27 (44.3)

Abbreviation: PD-L1 programmed cell death ligand-1, TPS tumor proportion score; ^astatistically significant

ISSN: 1471-2407